Novartis AG and Gilead Sciences Inc.'s recently acquired subsidiary Kite Pharma Inc. have the only two approved chimeric antigen receptor T cell (CAR-T) therapies, but bluebird bio Inc. and its partner Celgene Corp. were the stars of the recent American Society of Hematology (ASH) annual meeting.
What's New And What's Next In CAR-T After ASH
Incremental updates at the recent ASH meeting shed light on which products may follow Novartis' Kymriah and Gilead/Kite's Yescarta into the commercial market. Will it be Celgene and Bluebird or Celgene and Juno? Where do Pfizer, Servier and Cellectis stand with their off-the-shelf options?
More from Immuno-oncology
More from Anticancer
• By
The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.
• By
With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.
• By
Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicines could seal its leadership by combining zoldonrasib with other agents in its portfolio.